IGC Pharma Inc.

04/16/2024 | Press release | Distributed by Public on 04/16/2024 05:26

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two